Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Operating cash flow
Regeneron Pharmaceuticals, Inc.'s operating cash flow for fiscal 2025 was $5.0B, up 12.6% from $4.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.7B. Over the past ten years it has ranged from $1.3B (fiscal 2017) to $7.1B (fiscal 2021); the current reading is higher than 82% of that period. Regeneron Pharmaceuticals, Inc. ranks 1st of 611 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $5.0B | 12.63% |
| FY2024 | $4.4B | (3.78%) |
| FY2023 | $4.6B | (8.39%) |
| FY2022 | $5.0B | (29.18%) |
| FY2021 | $7.1B | 170.47% |
| FY2020 | $2.6B | 7.74% |
| FY2019 | $2.4B | 10.70% |
| FY2018 | $2.2B | 67.94% |
| FY2017 | $1.3B | (12.03%) |
| FY2016 | $1.5B | 11.66% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $813.0M | (24.65%) |
| Mar 2026 | $1.1B | (7.84%) |
| Dec 2025 | $1.2B | (27.68%) |
| Sep 2025 | $1.6B | 41.45% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $4.7B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $4.3B |
| RPRX Royalty Pharma PLC compare | $3.0B |
| ARGX argenex SE compare | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.5B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $911.8M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
| MRNA Moderna, Inc. compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.2B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement